On May 27, 2025, the new product launch of FattaLab® by Eieling Technology and the unveiling of the “Innovative Application Scenario Incubation Platform” and the Greater China “ELT+ Liver Screening Alliance” were successfully held. Eieling Technology launched a major innovative fatty liver detection product – FattaLab®. Many well-known industry experts, leaders, partners, and investors were invited to gather at the Hong Kong Science Park to witness Eieling Technology’s milestone in the field of liver health testing.
Innovative Exploration: A New Breakthrough in Fatty Liver Detection Technology
Before the new product launch, Eieling Technology CEO Jia Xiaojia delivered an opening speech, first expressing his sincere gratitude to the leaders at all levels and strategic partners present, and emphasized that Eieling Technology will continue to promote product iteration and upgrades, break through existing technological barriers with technological innovation, and benefit more liver disease patients.
CEO|Co-Founder of Eieling Xiaojia JIA
Mr Eric Or, Acting Chief Corporate Development Officer, Hong Kong Science & Technology Parks Corporation
In the Annual Review of the “Hong Kong LiverCare Project”, Zihao HUANG, PhD, Chief Research Officer of EIELING, systematically sorted out six typical screening scenarios in Hong Kong and presented them through multi-dimensional data, demonstrating Eieling’ technological leadership and social service value in large-scale grassroots early screening of liver disease.
Zihao HUANG, PhD, Chief Research Officer of EIELING
During the FattaLab® new product launch session, Tianyu JIANG, Product Marketing Director of EIELING, professionally interpreted the highlights of the new product from multiple angles, and fully demonstrated the upgrades and application value of the new product in terms of technological breakthroughs, weight, appearance, detection efficiency, and application prospects.
Tianyu JIANG, Product Marketing Director of EIELING
Afterwards, in the Unveiling Ceremony of The FattaLab® New Product Experience Officer, Professor Zheng Yongping, Chair Professor of Biomedical Engineering, The Hong Kong Polytechnic University, and Mr. Xiaojia JIA, CEO|Co-Founder of Eieling, jointly presented new products to the first batch of “New Product Experience Officers”.
Professor Zheng Yongping, Chair Professor of Biomedical Engineering, The Hong Kong Polytechnic University
Prof. Christopher Chao, Vice President (Research and Innovation), The Hong Kong Polytechnic University
Prof. Wai-Kay Seto, Department of Gastroenterology & Hepatology, Queen Mary Hospital, The University of Hong Kong
Mr. Patrick Lau, Deputy Executive Director of the Hong Kong Trade Development Council
Mr. Cai Qingsheng, Chairman of Guangzhou Doppler Electronic Technologies Co., Ltd.
From left to right: CEO|Co-Founder of Eieling Xiaojia JIA、Mr. Cai Qingsheng， Chairman of Guangzhou Doppler Electronic Technologies Co., Ltd.、Mr. Nixon Chung， Managing Director of Camloy International Limited, President of The Hong Kong Polytechnic University Shanghai Alumni Network、Prof. Christopher Chao， Vice President (Research and Innovation), The Hong Kong Polytechnic University、Prof. Wai-Kay Seto， Department of Gastroenterology & Hepatology, Queen Mary Hospital, The University of Hong Kong、Mr. Patrick Lau， Deputy Executive Director of the Hong Kong Trade Development Council、Mr. Zhong Yongxi， Chief China Representative of the Hong Kong Trade Development Council、Mr. Steve Zheng，Eieling Investor、Mr.Kelvin Wong， Director of Knowledge Transfer and Entrepreneurship Office, The Hong Kong Polytechnic University、Prof. Zheng Yongping， Chair Professor of Biomedical Engineering, The Hong Kong Polytechnic University
Two strategic cooperation signing ceremonies were held simultaneously at the FattaLab® new product launch site. This cooperation is of extraordinary significance. All parties uphold the belief of “making accurate testing accessible to every citizen” and take action to eliminate the harm of liver disease and build a solid line of defense for the liver health of the people.
Mr. Pan Hui， CEO of AUISET Biotechnology Co., Ltd.（Left）
Mr. Xiaojia JIA，CEO | Co-Founder of EIELING（Right）
Mr. Yin Hua， CEO of Guangzhou YouCareAI Co., LTD（Left）
Mr. Xiaojia JIA，CEO | Co-Founder of EIELING（Right）
At the launch event of Unveiling Ceremony of the “ELT+ Liver Screening Alliance” in the Greater China region, each expert conducted an in-depth discussion on the severe situation of fatty liver prevention and control in my country, and emphasized that early liver screening is the “first line of defense” to block the deterioration of liver disease. Alliance members will jointly promote the sinking of screening technology, work together, and fulfill the mission of “Healthy China”!
From left to right: CEO|Co-Founder of Eieling Xiaojia JIA、Dr. Wu Guoyi， Researcher, Shanghai Public Health Clinical Center, Fudan University、Prof. Zheng Qiuying， Director of the Department of Health and Pharmaceutical Industry, Beijing University of Chinese Medicine、Mr. Li Mingyang，Director of China Liver Health (CLH)、Prof. Wai-Kay Seto， Department of Gastroenterology & Hepatology, Queen Mary Hospital, The University of Hong Kong、Prof. Li Bo， Department of Hepatobiliary Surgery, Affiliated Hospital of Southwest Medical University、Prof. Lin Xuan， Department of Endocrinology, Nutrition, and Weight Management, CR & WISCO General Hospital、Prof. Zheng Yongping， Chair Professor of Biomedical Engineering, The Hong Kong Polytechnic University
Redefinition of technical boundaries and application paradigms for early screening of liver disease
The world’s first lightweight intelligent fatty liver assessment system FattaLab® released this time has achieved a technological breakthrough from “estimation” to “diagnosis level”, and can be regarded as a milestone product in the industry. FattaLab® integrates lightweight, portability, and personalization. It can complete liver data collection in 30 seconds, start and stop automatic analysis with one button, and output reports in real time through the mobile APP. It detects, intervenes, and ensures full-link management. The weight is reduced to 140g. It is the only product that achieves “medical-grade accuracy + quasi-home-level scenarios + closed-loop services”. FattaLab® undoubtedly redefines the technical boundaries and application paradigms of early screening for liver disease.
There are more than 3 billion patients with fatty liver worldwide, and 80% of them have no symptoms in the early stage. There are more than 200 million patients with chronic liver disease in my country, and the liver fibrosis screening rate of obese/diabetic high-risk groups is less than 15%. Fatty liver has become a problem that troubles many people. The emergence of FattaLab® is expected to promote liver health testing to become a necessary home health device like a blood pressure monitor and thermometer.
The successful launch of ElELING FattaLab® New Product Launch and the unveiling ceremony of “Innovative Application Scenario Incubation Platform” and the “ELT+ Liver Screening Alliance” in the Greater China highlight the innovative strength of FattaLab in precision medicine for liver diseases. In the future, Eieling will continue to deepen its technology and work with all parties to jointly promote the iterative upgrade of liver testing technology towards “non-invasive, accurate, and inclusive”, so that the concept of “early screening, early diagnosis, and early treatment” can be truly implemented.